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As more persons move into managed health-
care organizations, traditional tuberculosis (TB)
surveillance methods, which rely heavily on
information collected and channeled through the
public health system, may need to be supple-
mented. Accurate, complete surveillance infor-
mation is important for identification and follow-
up of persons with TB, as well as for accurate
assessment of the impact of TB on public health,
the effectiveness of control activities, and the
planning and prioritizing of interventions.
Automated data routinely collected by
managed care organizations may complement
TB surveillance obtained through reporting to
local and state health departments. In this study,
we evaluated the use of pharmacy dispensing
information and other inpatient and ambula-
tory-patient data routinely collected by managed
care organizations for identifying TB cases.
Methods
Study Population
The study population consisted of approxi-
mately 350,000 persons with pharmacy coverage
who received their care at one of the 14 Harvard
Pilgrim Health Care centers with automated
full-text medical records for ambulatory patients
and 100,000 persons with pharmacy coverage at
17 practices without such records within
Massachusetts from January 1, 1992, to June 30,
1996. Automated pharmacy and billing data,
however, were available for the entire study
population.
Identification of TB Cases from HMO Records
Ambulatory care, hospital, and emergency
room claims for the entire study population were
screened for any of 60 International Classifica-
tion of Diseases,, 9th Revision Clinical Modifica-
tion diagnosis codes or current procedures
terminology codes suggestive of TB. Automated
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Data collected by health maintenance organizations (HMOs), which provide
care for an increasing number of persons with tuberculosis (TB), may be used to
complement traditional TB surveillance. We evaluated the ability of HMO-based
surveillance to contribute to overall TB reporting through the use of routinely
collected automated data for approximately 350,000 HMO members. During
approximately 1.5 million person-years, 45 incident cases were identified in either
HMO or public health department records. Eight (18%) confirmed cases had not
been identified by the public health department. The most useful screening criterion
(sensitivity of 89% and predictive value positive of 30%) was dispensing of two or
more TB drugs. Pharmacy dispensing information routinely collected by many
HMOs appears to be a useful adjunct to traditional TB surveillance, particularly for
identifying cases without positive microbiologic results that may be missed by
traditional public health surveillance methods.780 780 780 780 780 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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Table 1. Components of the health maintenance organization-based screening criteria for tuberculosis (TB)
Code type Code Description of code
Antituberculosis drugs Antituberculosis drugs Antituberculosis drugs Antituberculosis drugs Antituberculosis drugs
Pharmacy dispensing Isoniazid
Pharmacy dispensing Ethambutol
Pharmacy dispensing Rifampin
Pharmacy dispensing Pyrazinamide
Pharmacy dispensing Streptomycin
Pharmacy dispensing Para-aminosalicyclic acid (PAS)
Pharmacy dispensing Kanamycin
Pharmacy dispensing Capreomycin
Pharmacy dispensing Cycloserine
Pharmacy dispensing Ethionamide
Microbiology codes Microbiology codes Microbiology codes Microbiology codes Microbiology codes
CPTa 87015 Concentration (any type) for parasites, ova, or tubercle bacillus (TB, AFB)
CPT 87116 Culture, tubercle, or other acid-fast bacilli; any source, isolation only
CPT 87117 Culture, tubercle, or other acid-fast bacilli; concentration plus isolation
CPT 87118 Culture, mycobacteria, definite identification of each organism
CPT 87190 Sensitivity studies, antibiotic; tubercle bacillus (TB, AFB), each drug
CPT 87206 Smear, primary source, with interpretation; fluorescent or acid-fast stain for
   bacteria, fungi, or cell types
ICD-9b procedure 90.4 Microscopy examination of sputum
ICD-9 procedure 90.41 Bacterial smear
ICD-9 procedure 90.42 Culture
ICD-9 procedure 90.43 Culture and sensitivity
ICD-9 procedure 90.49 Other microscopic examination
COSTARc TB234 AFB smear
COSTAR TB850 AFB culture and sensitivity
Radiology codes Radiology codes Radiology codes Radiology codes Radiology codes
CPT 71010 Chest, single view, frontal
CPT 71020 Chest, two views, frontal and lateral
CPT 71021 Chest with apical lordotic procedure
CPT 71030 Chest, complete, minimum of four views
CPT 71250 CT, thorax, without contrast
CPT 71260 CT, thorax, with contrast
CPT 71270 CT, thorax, without contrast, followed by contrast
CPT 71550 MRId chest
CPT 71555 MRI chest (excluding myocardium)
ICD-9 procedure 87.44 Chest X-ray
COSTAR TR027 Chest, PAe only
COSTAR TR028 Chest X-ray
COSTAR TR029 Chest, PA, and last with fluoroscopy
COSTAR TR032 Chest, fluoroscopy
COSTAR TR178 MRI-chest
COSTAR TR184 CATf scan-chest
COSTAR TR236 Chest, PA, and lateral
COSTAR TR237 Chest-PA, lateral, both obliques
COSTAR TR238 Chest-four views
COSTAR TR240 Chest-special views
aCPT, current procedures terminology.
b b b b bICD9, International Classification of Diseases, 9th revision.
c c c c cCOSTAR,  coding system used for the automated ambulatory-patient medical records (10).
dMRI, magnetic resonance imaging.
ePA, posteroanterior.
fCAT, computer-assisted tomography.
gPPD, purified protein derivative of tuberculin.
pharmacy records were searched for dispensing
of any of 10 antituberculosis medications during
the study period (Table 1). The automated
ambulatory-patient record, available for ap-
proximately 250,000 persons within our study
population, has been described in detail (1). The
automated medical record system uses standard-
ized forms that are completed for every patient
encounter at specific Harvard Pilgrim Health
Care centers, including telephone calls, office
visits, urgent care visits, and hospitalizations.
For each encounter, the provider either writes in
or selects from a list of all coded diagnoses, tests,
procedures, and prescriptions and enters
additional comments as free text. The automated
ambulatory-patient records were also screened781 781 781 781 781 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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Table 1, cont’d. Components of the health maintenance organization-based screening criteria for tuberculosis
(TB)
Code type Code Description of code
PPD PPD PPD PPD PPDg g g g g status  status  status  status  status
COSTAR DG249 Positive PPD
COSTAR DA129 Tuberculin conversion
Diagnosis codes for TB Diagnosis codes for TB Diagnosis codes for TB Diagnosis codes for TB Diagnosis codes for TB
COSTAR DR185 TB
COSTAR DG250 Pulmonary TB
COSTAR DG251 Active TB
ICD-9 diagnosis 010.0 Primary TB infection
010.1
010.8
ICD-9 diagnosis 011.0 Pulmonary TB
011.1
011.2
011.3
011.5
011.6
011.8
011.9,
011.90-011.96
ICD-9 diagnosis 012.0 Other respiratory TB
012.1
012.2
ICD-9 diagnosis 013.0 TB of meninges and central nervous system
013.1
013.2
013.3
013.4
013.5
ICD-9 diagnosis 015.0 TB of bones and joints
015.7
015.8
015.9
ICD-9 diagnosis 016.0 TB of genitourinary system
016.3
ICD-9 diagnosis 017.2 TB of peripheral lymph nodes
ICD-9 diagnosis 018.0 Miliary TB
018.8
018.9
ICD-9 diagnosis 795.3 Sputum positive only
Bronchoscopy and biopsy Bronchoscopy and biopsy Bronchoscopy and biopsy Bronchoscopy and biopsy Bronchoscopy and biopsy
ICD-9 procedure 33.22-33.24 Diagnostic procedures on lung and bronchus
33.26-33.28 Biopsy of lymphatic structure
40.11
aCPT, current procedures terminology.
b b b b bICD9, International Classification of Diseases, 9th revision.
c c c c cCOSTAR,  coding system used for the automated ambulatory-patient medical records (10).
dMRI, magnetic resonance imaging.
ePA, posteroanterior.
fCAT, computer-assisted tomography.
gPPD, purified protein derivative of tuberculin.
for any one of 17 coded diagnoses, tests, and
procedures suggestive of TB (Table 1).
Twelve combinations of screening codes
suggestive of active TB were used for automated
ambulatory-patient records, and five combina-
tions of screening codes were used for other
records (Table 2). To limit the number of persons
meeting screening criteria, we focused on
combinations of codes likely to have the highest
yield of TB cases. Cases that met any of these
screening criteria were assessed further.
Full-text ambulatory-patient medical records
were reviewed for all persons identified by
screening criteria who had automated ambula-
tory records. For individuals identified through
screening who did not have automated
ambulatory records, a modified version of the
Centers for Disease Control and Prevention’s782 782 782 782 782 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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Table 2. Performance of health maintenance organization-based screening criteria for tuberculosis (TB)
No. TB cases
    No.    detected No. TB cases  Positive
 meeting      using   unknown predictive
screening  screening    to public Sensitivity    value
Screening criteria   criteria    criteria  health dept.   (95% CI) (95% CI)
All patients (45 incident All patients (45 incident All patients (45 incident All patients (45 incident All patients (45 incident
   TB cases)    TB cases)    TB cases)    TB cases)    TB cases)
Two or more anti-TB drugsa 133 40 7   89 (76,96) 30 (22, 39)
Two or more anti-TB drugsa 108 39 7   87 (73,95) 36 (27,50)
  dispensed on the same date
Three or more anti-TB drugsa   76 38 7   84 (71,94) 50 (38,62)
Only patients with automated Only patients with automated Only patients with automated Only patients with automated Only patients with automated
  medical records (41 incident   medical records (41 incident   medical records (41 incident   medical records (41 incident   medical records (41 incident
   TB cases)    TB cases)    TB cases)    TB cases)    TB cases)
One or more anti-TB drugs,a a 132 21 2   51 (35, 67) 16 (10, 23)
  microbiology code,b and a
  radiology codec
At least one anti-TB druga and a 106 17 2   42 (26,58) 16 (10,24)
   CPTc code for mycobacterial
  culture/stain
Diagnosis coded for tuberculosis,   49 16 0   39 (24,56) 33 (20,48)
  a microbiology code,b and a
  radiology codec
Diagnosis coded for positive PPD,e 157   8 1   20  (9,35)   5 (2,10)
  a microbiology code,b and a
  radiology codec
At least one anti-TB druga and an   14   7 1   17  (7,32) 50 (23,77)
  ICD-9 diagnosis code for
  tuberculosis
ICD-9 procedure code for   15   1 0     2 (0.1,13)   7 (0.2,32)
  bronchoscopy, a microbiology
  code,b and a radiology codec
Diagnosis coded for active     4   1 0     2 (0.1,13) 25 (1,81)
  tuberculosis
Diagnosis coded for pulmonary   75   0 0     0   0
  tuberculosis
Diagnosis coded for tuberculin     1   0 0     0   0
  conversion, a microbiology code,b
  and a radiology codec
Only patients without Only patients without Only patients without Only patients without Only patients without
  automated medical   automated medical   automated medical   automated medical   automated medical
  records (4 incident TB cases)   records (4 incident TB cases)   records (4 incident TB cases)   records (4 incident TB cases)   records (4 incident TB cases)
ICD-9 diagnosis code 251   4 2 100 (40, 100)   2 (0.4, 40)
  for tuberculosis
A CPT code relating to   92   2 1   50 (7, 93)   2 (0.3, 8)
 mycobacterial culture/stain
  or a radiology code
aPharmacy dispensing data; antituberculosis drugs include isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin,
capreomycin, kanamycin, ethionamide, para-aminosalicyclic acid, and cycloserine.
bMicrobiology codes include COSTAR (coding system for automated ambulatory-patient records [10]) or ICD-9CM
(International Classification of Diseases, 9th Revision Clinical Modification) procedure codes for acid fast bacilli smear, culture
and sensitivities and microscopy examination of sputum.
cRadiology codes include current procedures terminology (CPT), COSTAR, or ICD-9 procedure codes for chest radiograph,
thoracic computer assisted tomography (CT), or thoracic magnetic resonance imaging (MRI).
dAmbulatory codes were obtained from automated ambulatory-patient records in the staff model division and from claims in the
network and group model division.
ePPD, purified protein derivative.783 783 783 783 783 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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(CDC) Report of Verified Case of Tuberculosis
form was sent to the primary-care physicians.
The form is routinely used to report to CDC
individual TB case information, including
clinical characteristics and laboratory results.
Our modified form included the question “While
under your care, did this patient have suspected
and/or confirmed ACTIVE tuberculosis?” If “Yes”
was checked, the full-text medical records of the
person were reviewed. In addition, the medical
records of a random sample of 10% of the patients
with questionnaires returned by providers were
reviewed to validate the use of data obtained
from questionnaire results. A case of TB was
defined according to the CDC surveillance
definition (2). A culture-positive case is defined
as isolation of Mycobacterium tuberculosis from
a clinical specimen. A smear-positive case is
defined as demonstration of acid-fast bacilli
(AFB) in a specimen if either a culture was not
obtained or results were unknown. In the
absence of laboratory evidence of disease, a
clinical case is one that meets the following
criteria: a positive tuberculin skin test, a
completed diagnostic work-up, clinical evidence
and signs and symptoms compatible with TB, an
abnormal and unstable (worsening or improv-
ing) chest radiograph if intrathoracic disease is
present, and treatment with two or more
antituberculosis drugs. All cases without a
positive culture for M. tuberculosis that were not
known to the public health department were
verified by review with the Massachusetts State
Tuberculosis Control Officer, using all available
primary patient data from the ambulatory-
patient medical record, public health records,
and hospital records.
Identification of TB Cases from Public Health
Department Records
Reporting of confirmed or clinically suspected
TB cases to the Massachusetts Department of
Public Health by health-care providers, laboratories,
boards of health, or administrators of hospitals is
mandatory. In addition, the Massachusetts State
Laboratory Institute performs susceptibility testing
on most M. tuberculosis isolates in Massachusetts
and provides the public health department with
direct access to microbiology information about
virtually all persons in Massachusetts with
culture-positive  M. tuberculosis. All verified  cases
are entered into the public health TB registry.
The entire HMO population was matched to
the public health TB registry by using limited
patient identifiers (first two letters of last name,
first two letters of first name, month and year of
birth, and sex) to maintain patient confidential-
ity. Potential matches were confirmed by using
full identifiers. This method for matching
registries with minimal disclosure of individual
identities is described elsewhere (3).
Analysis
The sensitivity, defined as the proportion of
TB cases detected by either HMO-based
screening criteria or routine public health
surveillance, was determined by comparison
with any verified TB case identified through
public health or HMO records. Positive
predictive value was defined as the proportion of
persons with verified TB meeting screening
criteria. Exact binomial confidence intervals
were calculated for sensitivity and positive
predictive value (4). The performance of the
different screening rules for detecting TB was
compared.
Results
In approximately 1.5 million person-years,
768 persons met at least one of the HMO-based
screening criteria, with a positive screening
criteria rate of 0.4 per 10,000 person-years
among persons with automated ambulatory-
patient records and 0.7 per 10,000 person-years
among those without such records. Thirty-nine
(9%) incident TB cases were identified among the
415 persons with automated ambulatory-patient
records who met screening criteria, and 4 (1%)
incident TB cases were identified among the 353
persons without automated ambulatory records
who met screening criteria. The response rate to
the provider questionnaire was 100%, as was the
agreement rate between classification of TB
cases based on provider questionnaire results
and on-site medical record review.
Thirty-five (81%) of the 43 incident TB cases
detected by HMO-based screening had been
identified previously by the public health
department. Of these 35 cases, 32 were culture-
positive, and three met the clinical case
definition. Two additional TB cases, both of
which were culture-positive, were known to the
public health department but did not meet HMO-
based screening criteria. These two patients784 784 784 784 784 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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received treatment and medication from state-
funded TB clinics. Thus, 45 cases were identified
through either HMO-based screening or public
health department records. All 45 cases met the
CDC surveillance definition. Eight (18%) of these
cases were unknown to the public health system.
Most cases (41 of 45) were diagnosed at one of the
HMO centers with automated ambulatory-
patient records, a proportion consistent with the
concentration of urban regions within their
catchment areas. The rates were approximately
11.7 TB cases per 100,000 population among
HMO members with automated ambulatory-
patient records and four TB cases per 100,000
population among those without such records.
The sensitivity of each of the screening
criteria was 0% to 100%, and the positive
predictive value was 0% to 52% (Table 2).
Screening criteria based on pharmacy dispens-
ing information had the best combinations of
sensitivity and positive predictive value. Two or
more dispensed antituberculosis drugs, combin-
ing the results for persons with and without
automated ambulatory-patient records, had an
overall sensitivity of 89% (95% confidence
interval [CI] = 76%, 96%) and positive predictive
value of 30% (95% CI = 22%, 39%). Three or more
antituberculosis drugs had an overall sensitivity
of 84% (95% CI = 71%, 94%) and positive
predictive value of 50% (95% CI = 38%, 62%), and
two or more antituberculosis drugs dispensed on
the same date had an overall sensitivity of 87%
(95% CI = 73%, 95%) and positive predictive
value of 36% (95% CI = 27%, 50%). The
differences between the performance of two or
more dispensed antituberculosis drugs among
persons with automated ambulatory-patient
records (sensitivity = 90%, positive predictive
value = 34%) and persons without automated
records (sensitivity = 75%, positive predictive
value = 12%) were not statistically significant,
although the small number of TB cases in each
group limits the power to detect a difference.
Among the 71 persons with automated
ambulatory-patient records who received two or
more antituberculosis drugs but did not have
incident TB, 9 (13%) had active TB diagnosed
outside the study period, 23 (32%) were treated
for other mycobacterial infections, 11 (15%)
received more than one drug during TB
prophylaxis, 2 (3%) received drugs for multiple
unrelated conditions (e.g., rifampin for
eradication of Staphylococcus aureus; ethambu-
tol for M. avium complex prophylaxis), and the
remaining 26 (37%) were suspected of having
active TB without subsequent confirmation
(Table 3).
Of the 118 persons with automated
ambulatory-patient records who met screening
criteria involving a diagnosis code for TB but did
not have incident TB, 57 received the diagnosis
code as an indication of routine prenatal
screening for TB, 12 had a previous history of TB,
31 were suspected of having active TB without
subsequent confirmation, and 18 had the
diagnosis code documented in their HMO
ambulatory medical record for no apparent
reason (Table 3).
Of the eight patients whose cases had not
been identified by the public health department,
seven were culture-negative and met the TB
clinical case definition, and one did not have a
microbiology culture and met the smear-positive
TB case definition. Three of the patients had
AFB smear-positive pathology specimens; of
these, two had negative cultures for
M. tuberculosis, and one did not have a culture
performed. Of the eight cases, one involved
pulmonary TB, and the remaining seven were
extrapulmonary. One patient was 2 years old at
the time of diagnosis; the remaining seven were
18 years of age or older. All cases were confirmed
by review with the Massachusetts State
Tuberculosis Control Officer. Of these eight
cases, seven were detected by the two or more
antituberculosis drug screening criterion.
Conclusions
Since the establishment of a national
surveillance system for TB in 1953, TB
surveillance has depended on laboratories,
public health clinics, and reporting by private
practitioners. Several retrospective studies
performed by local TB programs suggest that TB
cases may be underreported (5-7). Although
ascertainment of culture-positive cases is likely
to be nearly complete, since laboratories are
required by law in most states to report isolation
of  M. tuberculosis to the state health
department, surveillance for cases lacking
positive cultures depends largely on reporting by
health-care providers or referrals to public
health clinics for treatment. Underreporting of
TB cases without positive cultures may
contribute to incomplete surveillance. A study
assessing the completeness of TB case reporting785 785 785 785 785 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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Table 3. Reasons for meeting screening criteria among individuals without incident tuberculosis (TB) who had
automated ambulatory-patient records
Screening criteria that include a TB diagnosis code or multiple anti-TB drugs
Diagnosis codeb
     for TB,
a microbiology     At least one
Reasons why Two or more Diagnosis    Diagnosis  code,c and a anti-TB druga and
non-TB cases met     anti-TB  codeb for     codeb for   a radiology an ICD-9 diagnosis
screening criteria     drugsa active TB pulmonary TB       coded      code for TB
Active TB diagnosed   9 (13%) 0   0   0 0
 outside study window
Suspected active TB 26 (37%) 2 (67%)   4 (5%) 19 (58%) 6 (86%)
TB prophylaxis 11 (15%) 0   0   0 0
Prenatal TB screening   0 0 57 (76%)   0 0
Prior history of TB   0 0   5 (7%)   7 (21%) 0
Other mycobacterial 23 (32%) 0   0   0 0
  infections
Treatment of other   2 (3%) 0   0   0 0
  conditions
No documentation of   0 1 (33%)   9 (12%)   7 (21%) 1 (14%)
  reason in HMO
  medical record
Total no. without 71 3 75 33 7
  incident active TB
aPharmacy dispensing data; antituberculosis drugs include isoniazid, rifampin, pyrazinamide, ethambutol, streptomycin,
capreomycin, kanamycin, ethionamide, para-aminosalicyclic acid, and cycloserine.
bAmbulatory codes were obtained from automated ambulatory records in the staff model division and from claims in the network
and group model division.
cMicrobiology codes include COSTAR (coding system for automated ambulatory-patient records [10]) or ICD-9CM (International
Classification of Diseases, 9th Revision Clinical Modification) procedure codes for acid fast bacilli smear, culture and
sensitivities and microscopy examination of sputum.
dRadiology codes include current procedures terminology (CPT), COSTAR, or ICD-9 procedure codes for chest radiograph,
thoracic computer- assisted tomography (CT), or thoracic magnetic resonance imaging (MRI).
in Puerto Rico (6) found that 19.5% of patients
with TB were not reported, partly because of
underreporting of cases without positive cul-
tures for M. tuberculosis.
The recent shift into managed care of
populations at high risk for TB, including
Medicaid and Medicare recipients, has raised
additional concern about the continued com-
pleteness of reporting. However, HMOs rou-
tinely collect information that can be used to
identify persons likely to have TB. McCray et al.
(6) noted that, according to pharmacy prescrip-
tion data in Maryland, the cases of 19% of
patients receiving two or more antituberculosis
drugs had not been reported to the public health
department; however, the patients’ medical
records were not reviewed to verify a diagnosis of
active TB. Maggini et al. (8) evaluated the use of
Italy’s National Health Service pharmacy
dispensing information to identify TB cases in
the province of Rome and found that pharmacy
screening detected seven times more new TB
cases than routine passive surveillance. Hripcsak
et al. (9) evaluated a number of screening rules
based on automated information available at an
urban medical center in New York City         and
found that inpatient use of antituberculosis
drugs had a sensitivity of 68% and a positive
predictive value of <1% for detecting TB cases
based on their health department’s TB registry.
These investigators did not, however, have
access to records of antituberculosis drugs
received by ambulatory patients and did not
specifically evaluate the use of more than one
antituberculosis drug as a screening criterion.
No previous study has compared the utility of
pharmacy data with that of other automated
administrative or health-care data.
Of the screening criteria evaluated in our
study, dispensing of two or more antituberculosis
drugs was the most useful, with an overall
sensitivity of 89%. The most common reasons for786 786 786 786 786 Emerging Infectious Diseases Vol. 5, No. 6, November–December 1999
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dispensing of two or more antituberculosis drugs
to persons without TB were the empiric use of
antituberculosis drugs for suspected active TB
(37%) and the use of antituberculosis drugs for
treatment of mycobacterial infections other than
TB (32%). In addition, 15% of patients without
TB received more than one drug for TB
prophylaxis, which can occur, for example, when
isoniazid is switched to another antituberculosis
drug because of adverse drug reactions. A
possible strategy for improving the positive
predictive value of screening criteria based on
pharmacy dispensing information is the use of
more rigorous criteria, such as dispensing of
three or more antituberculosis drugs (positive
predictive value = 50%), or restricting the timing
of drug dispensing, such as requiring that two or
more antituberculosis drugs be dispensed on the
same date (positive predictive value = 36%). The
improvement in positive predictive value for
these more rigorous criteria, however, must be
weighed against loss of sensitivity in identifying
TB cases. For our HMO study population,
requiring three or more antituberculosis drugs
missed two TB cases, and requiring that two or
more drugs be dispensed on the same date
missed one case detected by the less stringent
criterion. The choice of the screening criterion
with the most useful balance between sensitivity
and specificity depends in part on the
surveillance strategy used.
Surveillance based on HMO pharmacy
dispensing information can be used to identify
HMO enrollees most likely to have active TB, so
that efforts can be focused on additional
evaluation of these persons. As with traditional
TB surveillance methods, surveillance based on
pharmacy dispensing information requires
information from the patients’ medical records to
verify whether the TB case definition is satisfied.
Using this surveillance strategy, screening for
two or more antituberculosis drugs would
require reviewing the medical records of
approximately three patients to identify each
case of incident active TB. We feel that the
positive predictive value of 30% is sufficient to
make this surveillance screening method
practical if it can be applied in other managed
care settings.
The positive predictive values of screening
criteria that include TB diagnosis codes are
limited by a number of factors. TB diagnosis
codes, for example, were frequently used for
patients with suspected active TB during the
weeks required for diagnostic work-up or
observation for clinical response to therapy.
These codes were also frequently used to indicate
that routine TB skin testing had been performed
rather than to indicate the presence of active
disease or prior history of TB.
The difference in the TB case rates between
HMO members with automated ambulatory-
patient records (approximately 11.7 TB cases per
100,000 population) and members without such
records (approximately four TB cases per
100,000 population) in our study could either
reflect a true difference in the underlying risk for
TB in the two populations or case ascertainment
bias resulting from differences in the methods
used to identify TB cases. The former
explanation is more likely for several reasons.
First, the HMO health centers with automated
ambulatory-patient records serve a largely
urban population concentrated in the Boston
area, while the HMO-affiliated practices without
such records serve a largely suburban popula-
tion. The difference in the rates found in our
study mirrors the difference in the 1992 to 1998
TB case rate averages reported by the
Massachusetts Department of Public Health for
the city of Boston (17.7 TB cases per 100,000
population) compared with the rest of the state of
Massachusetts (4.1 TB cases per 100,000
population). Second, the match between the
health department’s TB registry and the HMO
membership list did not identify any TB patients
who had not previously been detected through
screening criteria and record review based on
our modified RVCT results among HMO
members without automated ambulatory patient
records. This argues against inadequate case
finding resulting in apparent lower TB case rates
in this group.
A substantial number of TB cases in our
study were unknown to the public health
department (18% of cases among our HMO study
population). This proportion is comparable with
the fraction described in the studies cited above.
Underreporting of these cases compromises the
usefulness of TB surveillance. Screening for
dispensing of antituberculosis drugs may be a
particularly useful method for identifying cases
without positive cultures for M. tuberculosis that
might otherwise be missed by routine surveil-
lance methods dependent on laboratory- and
provider-based reporting.787 787 787 787 787 Vol. 5, No. 6, November–December 1999 Emerging Infectious Diseases
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The positive predictive value of screening
criteria based on the dispensing of antituberculo-
sis drugs may also be limited to some degree in
clinical settings where many patients receive
these medications for other indications, includ-
ing other mycobacterial infections (e.g., in cases
of HIV infection). Strategies that could be
applied in such settings include excluding those
persons also receiving medications frequently
used for treatment of M. avium complex
infections (e.g., clarithromycin). During our
study period, however, more than 1,000 known
HIV-infected patients were treated in HMO
centers with automated ambulatory-patient
records, of whom only 23 (Table 3) had false-
positive cases identified by the two or more TB
drug criterion. In addition, widespread imple-
mentation of new CDC recommendations for use
of multidrug therapy for TB prophylaxis may
require modification of the screening criteria.
One possible strategy would be to require that
antituberculosis drugs be dispensed over a
minimum time interval (e.g., >4 months).
Although TB surveillance based on phar-
macy dispensing information depends upon
availability of automated pharmacy data, such
data are available for most of the U.S.
population, including most Medicaid and
Medicare recipients. Our results indicate that
pharmacy dispensing information routinely
collected by many HMOs has high sensitivity
and reasonable positive predictive value and is
particularly useful for identifying TB cases
without positive cultures, which may be missed
by traditional public health surveillance.
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